Multisite Clinical Trials

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

WF2304-COSMIC, Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

ALTE2131, Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Genomically-Guided Treatment Trial in Brain Metastases

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors

A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers

Cancer Moonshot Biobank Research Protocol

EAQ222CD: “Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients”

S2013 “Immune Checkpoint Inhibitor Toxicity (I-CHECKIT):  A Prospective Observational Study”

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Stratum 2 of AGCT1531 (Low Risk, Stage I Non-Seminoma MGCT), has been temporarily closed to accrual as of December 17, 2024, pending an evaluation of patients currently enrolled on this study. 

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

COG-ANHL2121: Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Age: 180 days- <22 years (at time of study enrollment).